Fuda Cancer Hospital
Fuda Cancer Hospital
China, Cantão
| China | Turki | Austria | |
| Terapi sinar proton | dari $36,500 | dari $70,000 | dari $80,000 |
| Terapi radiasi untuk kanker kolorektal | dari $11,500 | dari $7,000 | dari $12,000 |
| Terapi proton untuk kanker prostat | dari $42,500 | dari $30,000 | dari $80,000 |
| Terapi proton untuk kanker payudara | dari $38,500 | dari $30,000 | dari $55,000 |
| Terapi Radiasi untuk Sarkoma | dari $10,500 | dari $3,250 | dari $18,000 |
Bookimed tidak menambah biaya tambahan dalam harga perawatan Sarkoma. Tarif berasal dari daftar harga resmi klinik. Anda membayar langsung di klinik saat tiba di negara tujuan untuk perawatan Anda.
Bookimed berkomitmen pada keselamatan Anda. Kami hanya bekerja dengan institusi medis yang menjaga standar internasional tinggi dalam perawatan Sarkoma dan memiliki izin yang dibutuhkan untuk melayani pasien internasional di seluruh dunia.
Bookimed menawarkan bantuan ahli gratis. Koordinator medis pribadi mendukung Anda sebelum, selama, dan setelah perawatan, menyelesaikan semua masalah Anda. Anda tidak pernah sendirian dalam perjalanan perawatan Sarkoma Anda.
Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.
He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.
His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.
China offers advanced sarcoma therapies including domestically developed proton systems and targeted drug combinations. Key technologies include cryosurgery, NanoKnife, and carbon ion radiotherapy for radioresistant tumors. Specialized centers utilize multi-target inhibitors like Anlotinib and solid-tumor CAR-T treatments within JCI-accredited facilities.
Bookimed Expert Insight: Analysis of JCI-accredited facilities in Guangzhou reveals a specialization in late-stage oncology. Fuda Cancer Hospital has treated over 30,000 patients from 100 countries using minimally invasive tools. This volume suggests high expertise in using NanoKnife and cryosurgery for complex sarcomas.
Patient Consensus: Patients note that medical technology in top Chinese cities is excellent and well-equipped. They emphasize the importance of using professional support to manage complex communication during advanced treatments.
Top sarcoma centers in China include JCI-accredited facilities like Fuda Cancer Hospital in Guangzhou and national oncology hubs. These centers specialize in limb-sparing surgeries, cryosurgery, and advanced radiotherapy. Facilities in Beijing and Shanghai lead in complex multidisciplinary care for bone and soft tissue tumors.
Bookimed Expert Insight: Fuda Cancer Hospital serves over 30,000 international patients and specializes in late-stage care. They offer 10 types of minimally invasive therapies as alternatives to traditional chemotherapy. This is particularly valuable for patients who cannot tolerate the systemic side effects of aggressive drugs.
Patient Consensus: Patients note that leading Chinese centers are well-equipped with experienced doctors. Many emphasize the importance of finding hospitals with English-speaking support to navigate specialized care smoothly.
Leading Chinese cancer centers maintain international benchmarks through Joint Commission International accreditation and specialized oncology certifications. Facilities like Fuda Cancer Hospital utilize JCI-accredited protocols. These centers often employ advanced technologies like proton-beam therapy and high-intensity focused ultrasound for complex sarcoma cases.
Bookimed Expert Insight: While many domestic hospitals shift toward the ISQua-recognized 2021 Edition standards, Fuda Cancer Hospital remains a primary choice for international patients due to its JCI accreditation and focus on late-stage cases. Their model emphasizes niche minimally invasive therapies like NanoKnife rather than standard systemic chemotherapy, which attracts patients seeking alternatives to traditional Western protocols.
Patient Consensus: Patients value the high-quality diagnostics and affordability of PET scans compared to Western costs. However, many emphasize the importance of bringing an independent advocate to manage communication and ensure multidisciplinary care during treatment.
Chinese hospitals conduct many clinical trials for rare sarcoma subtypes that accept international patients. China manages approximately 39% of global oncology trials. Facilities like Fuda Cancer Hospital utilize JCI-accredited protocols and advanced technologies including NanoKnife and cryosurgery to treat over 30,000 international patients from 100 countries.
Bookimed Expert Insight: While Chinese research is vast, focusing on JCI-accredited private oncology centers like Fuda Cancer Hospital simplifies enrollment. These facilities are specifically designed for international logistics. They offer over 10 types of minimally invasive therapies that often serve as trial alternatives. Choosing these centers avoids the eligibility barriers commonly found in public academic hospitals.
Patient Consensus: Patients note it is important to act quickly because digitalized systems often allow treatment plans within days. Many emphasize checking the ChiCTR registry directly or using local coordinators to navigate potential language and visa requirements.
Sarcoma treatment in China usually requires stays between 30 and 180 days. Patients typically use an S2 visa for standard therapy or an S1 visa for long-term care exceeding six months. Essential requirements include a formal invitation letter from a licensed Chinese hospital and proof of financial capacity.
Bookimed Expert Insight: JCI-accredited centers like Fuda Cancer Hospital in Guangzhou are popular for complex sarcoma cases. This hospital alone has treated over 30,000 patients from 100 countries. Choosing an accredited facility simplifies the visa process because their invitation letters carry significant weight with consulates. These centers often specialize in minimally invasive techniques like NanoKnife and cryosurgery. This can sometimes reduce the recovery portion of your stay compared to traditional open surgeries.
Patient Consensus: Patients emphasize starting the visa application at least six to eight weeks before travel. Many recommend translating medical records into Chinese early to prevent diagnostic delays once they arrive.
Major JCI-accredited cancer centers in China provide dedicated English-language support through international patient departments. These facilities offer medical interpreters, bilingual coordinators, and translated documentation. Clinical English proficiency varies among medical staff. Bookimed manages logistics and communication with specialized oncology teams.
Bookimed Expert Insight: While Fuda Cancer Hospital serves over 30,000 international patients, language barriers still exist during bedside nursing care. We find that JCI-accredited facilities maintain higher standards for written medical translations. Patients should prioritize hospitals with international departments to ensure complex pathology reports are accurately explained.
Patient Consensus: Patients note that hiring independent support is helpful because hospital interpreters are sometimes administrative staff. Clear communication regarding medication dosages is vital to avoid post-operative confusion.